Business Context and Reporting Period
Cytosorbents Corp filed this Form 8-K on June 21, 2013, to report the entry into a material definitive agreement involving the issuance of convertible notes and warrants to accredited investors. The filing also references a press release dated June 27, 2013, regarding a new US Army contract.
Key Financial Metrics
- Debt Issuance: $1,098,000 in aggregate principal amount of convertible notes.
- Interest Rate: 8% annual rate.
- Maturity: One year from the closing date (June 21, 2014).
- Conversion Terms: Automatic conversion at $0.125 per share; full conversion yields 8,784,000 shares of common stock.
- Warrants: Issued with 50% coverage, exercisable at $0.15 per share.
- Repayment: The notes are not required to be repaid in cash; they convert to equity.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, or liquidity metrics.
Material Changes
The primary material change is the increase in capital obligations through the issuance of $1,098,000 in convertible debt. Additionally, the company announced the commencement of a $1 million US Army Phase II SBIR contract, representing a new revenue stream, though specific financial impact details are not quantified in this filing.
Guidance, Outlook, and Risks
- Outlook: Management highlighted the start of the US Army Phase II SBIR contract as a positive development.
- Risks/Contingencies: The notes do not contain anti-dilution provisions. There are no registration rights on the underlying common stock. The securities were issued under Section 4(2) and Rule 506 exemptions, restricting transferability.
- Unusual Items: The debt instrument is structured to convert automatically into equity rather than requiring cash repayment.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-conversion to assess dilution impact.
- Confirm the status and payment schedule of the $1 million US Army Phase II SBIR contract.
- Review the full text of the Convertible Note (Exhibit 4.1) and Warrant (Exhibit 4.2) for specific covenants not detailed in the summary.
- Check subsequent filings for any changes in the company's cash position resulting from this funding.